司库奇尤单抗联合莪仙化斑汤对斑块型银屑病患者中医证候积分及甲皱襞微循环形态的影响

Effect of secukinumab combined with E'xian Huaban Decoction on traditional Chinese medicine symptom scores and nailfold microcirculation morphology in patients with plaque psoriasis

  • 摘要:
    目的 探讨司库奇尤单抗联合莪仙化斑汤对斑块型银屑病患者中医证候积分及甲皱襞微循环形态的影响。
    方法 选取120例斑块型银屑病患者为研究对象,并随机分为单药组(n=60)及联合组(n=60)。单药组给予司库奇尤单抗治疗,联合组在单药组基础上联合莪仙化斑汤治疗。观察2组患者的临床治疗效果、中医证候积分(皮损、瘙痒、皮肤甲错、鳞屑和心烦)、相关量表银屑病面积和严重程度指数(PASI)、皮肤病生活质量指数(DLQI)和视觉模拟评分法(VAS)评分、炎症因子白细胞介素-17(IL-17)、白细胞介素-23(IL-23)和血管内皮生长因子(VEGF)水平以及甲皱襞微循环形态(袢管形态、血流状态和袢周状态)。
    结果 联合组的临床治疗总有效率为95.00%, 高于单药组的83.33%,差异有统计学意义(P < 0.05)。治疗后, 2组中医证候积分(皮损、瘙痒、皮肤甲错、鳞屑和心烦)、炎症因子(IL-17、IL-23和VEGF)水平、各量表(PASI、DLQI和VAS)评分和袢管形态积分、血流状态积分、袢周状态积分低于治疗前,且联合组低于单药组,差异有统计学意义(P < 0.05)。
    结论 司库奇尤单抗联合莪仙化斑汤可显著改善患者临床症状及体征,提高临床治疗效果。

     

    Abstract:
    Objective To investigate the effects of secukinumab combined with E'xian Huaban decoction on traditional Chinese medicine symptom scores and nailfold microcirculation morphology in patients with plaque psoriasis.
    Methods A total of 120 patients with plaque psoriasis were selected and randomly divided into monotherapy group (n=60) and combination therapy group (n=60). The monotherapy group received secukinumab treatment, while the combination therapy group was treated with secukinumab plus E'xian Huaban Decoction. Clinical therapeutic efficacy, traditional Chinese medicine symptom scores (including skin lesions, pruritus, rough skin, scales and irritability), relevant scale Psoriasisarea and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and Visual Analogue Scale (VAS) scores, inflammatory factors interleukin-17 (IL-17), interleukin-23 (IL-23) and vascular endothelial growth factor (VEGF) levels and nailfold microcirculation morphology (loop tube morphology, blood flow state and loop periphery state) were observed in both groups.
    Results The overall clinical efficacy rate in the combination therapy group was 95.00%, which was significantly higher than 83.33% in the monotherapy group (P < 0.05). After treatment, traditional Chinese medicine symptom scores (skin lesions, pruritus, rough skin, scales and irritability), inflammatory factors (IL-17, IL-23 and VEGF) levels, scale (PASI, DLQI and VAS) scores as well as loop tube morphology scores, blood flow state scores and loop periphery state scores were significantly lower compared to pre-treatment values, and these parameters were significantly lower in the combination therapy group than the monotherapy group (P < 0.05).
    Conclusion Secukinumab combined with E'xian Huaban Decoction can significantly improve clinical symptoms and signs, and enhancing the clinical therapeutic effect.

     

/

返回文章
返回